Abstract
One known adverse event associated with dimethyl fumarate (DMF) is grade III lymphopenia which usually resolves within 2–3 months upon DMF discontinuation. Here, we report a case of a 50-year-old woman with MS who developed grade III lymphopenia within 6 months of DMF initiation, and despite treatment cessation within the next 6 months, she has continued to have severe persistent lymphopenia for over 5 years. Our observation suggests prolonged and possibly irreversible lymphopenia as a possible adverse event of DMF, and it emphasizes the need for monitoring lymphocyte numbers, and to cease dosing promptly after onset of grade III lymphopenia.
Original language | English (US) |
---|---|
Pages (from-to) | 1306-1308 |
Number of pages | 3 |
Journal | Multiple Sclerosis Journal |
Volume | 27 |
Issue number | 8 |
DOIs | |
State | Published - Jul 2021 |
Keywords
- Tecfidera
- adverse event
- dimethyl fumarate
- lymphopenia
- pharmacovigilance
ASJC Scopus subject areas
- Neurology
- Clinical Neurology